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Study is valid and helps define
proper role of surveillance
Our publication is the first randomized controlled trial
that has studied the influence of flow (Qa) surveillance
on graft survival [1]. We share the disappointment of the
nephrology community that surveillance did not prolong
graft life.
Dr. Levine questions the validity of our study because
we did not apply decrease in Qa (Qa), and did not re-
strict Qa measurements to early in dialysis. Our observa-
tion that Qa does not improve prediction of thrombosis
[2] was confirmed by a second study that was reviewed
by two statisticians [3]. In addition, we have shown that
hemodynamic variation is so great that there is no value
in limiting measurements too early in dialysis [1]. More-
over, risk of thrombosis increases with ultrafiltration vol-
ume [3]. This indicates that hemodynamic state at the end
of dialysis influences thrombosis, suggesting that it may
be better to measure Qa late rather than early in dialysis.
Dr. Levine has restated criticisms made by Krivitski
and Gantela [4, 5] concerning our study that evaluated
accuracy of Qa in predicting thrombosis [2].
(1) They claimed our calculations had multiple errors
because a figure and a table did not have equal numbers of
false positives [4]. This difference was expected because
these two analyses did not include the same number of
grafts [2]. The only error was in calculating predictive ac-
curacy of Qa and Qa with the data in Table 1. Correction
yielded a lower predictive accuracy [6].
(2) They claimed that reanalysis of our data shows Qa
accurately predicts thrombosis [4]. Their analysis is not
valid because they only considered Qa; they excluded
grafts that thrombosed before Qa could be measured.
Inclusion of all grafts yields a poor predictive accuracy
(Table 1).
Table 1. Original data used to determine accuracy of Qa and Qa
(combined as either/or) in predicting thrombosis [2, 6]a
Negative test Positive test
Qa ≥ 600 mL/min and Qa < 600 mL/min or
Qa < 20% Qa ≥ 20%
Patient 30 9
Thrombosed 18 26
aSensitivity, 59%; false positive rate, 23%. Eighteen of 44 thrombosed grafts
did so without warning. Table includes 8 grafts that thrombosed before Qa
could be measured. Predictive accuracy was optimized by predicting outcome
within 1 month and measuring Qa over 3 months.
(3) They criticized our suggested guideline for ade-
quate predictive accuracy [5]. Actual predictive accuracy
was so poor that this criticism is irrelevant.
(4) They claimed we “have no basis for making any
conclusions” without doing a harm-benefit analysis [5].
They have not applied this criticism to studies that favor
Qa surveillance, and the information required to do such
an analysis is not available [6].
In conclusion, our surveillance study [1] was properly
designed, and our studies convincingly show that Qa is
an inaccurate predictor of thrombosis [2, 3, 6]. Only by
considering the results of such ongoing research can we
hope to define the proper role of surveillance.
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Markers of oxidative stress
in uremia
To the Editor: In their recent paper, Witko-Sarsat et al
[1] hypothesized that advanced oxidation protein prod-
ucts (AOPP) behave as mediators of inflammation. A
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specific AOPP prepared in vitro by exposure of human
serum albumin (HSA) to HOCl displayed properties sim-
ilar, yet not identical, to those products isolated from
blood of uremic patients. According to the authors, dif-
ferent properties may originate from a heterogeneous
nature of the whole AOPP. This indeed may be a
very important albeit not sufficiently recognized fact. In
1995, we reported on a macromolecular protein com-
plex (MPC) present in increased quantities in blood
of diabetic patients with nephropathy [2], the molec-
ular properties of which are similar, if not identi-
cal, to AOPP. Although we have suspected that MPC
may contain free radical–modified HSA, no such anti-
gen could be detected by a specific enzyme-linked im-
munosorbent assay (ELISA) test. However, we have
subsequently documented the presence in MPC of
both fibrinogen A alpha chain and triglyceride-rich
lipoprotein.
Moreover, we were able to prepare a similar complex
in vitro by exposure of plasma to a hydroxyl radical gen-
erating system [3]. Because the system contained ascorbic
acid and a transition metal, it was suggestive that MPC
may be formed in vitro by a reductive rather than oxida-
tive conditions.
In conclusion, it appears that both MPC and AOPP
represent the same class of free radical–modified proteins
circulating in blood of uremic patients. It is, however, not
clear whether these products are formed by the action of
oxidizing or reducing radical oxygen species [4].
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Reply from the Authors
We wish to thank Dr. Lipinski for his most perti-
nent remarks. We agree that the species isolated from
the blood of diabetic patients, macromolecular complex
protein complex (MPC), described in the laboratory of
Dr. Lipinski could, most likely, be included in the group
of oxidatively-modified proteins including advanced oxi-
dation protein products (AOPP) [1].
We have recently obtained information on the bio-
chemical and molecular characteristics of AOPP. The use
of various analytical techniques enabled localizing and
identifying the main oxidized proteins in hemodialysis
(HD) plasma with human serurm albumin (HAS). To in-
terpret the spectral modifications detected in HD plasma
fractions we described in detail some structural modifi-
cations that occur as a result of plasma or HSA treat-
ment with HOCl. Our results indicate that HOCl, and
not NO2 generated by myeloperoxidase (MPO), repre-
sents a pathway for AOPP production in plasma proteins
exposed to activated phagocytes (manuscript submitted
for publication). However, this pathway is not exclusive
and other oxido-reduction reactions may occur.
The fact that MPC did not react in an enzyme-linked
immunosorbent assay (ELISA) specific for the detection
of oxidized proteins might be due to restricted epitopes,
which might not be apparent on MPC. Therefore, the
presence of oxidatively modified protein features in MPC
could not be ruled out. Interestingly, MPC contained
fibrinogen A alpha chain and triglyceride-rich lipopro-
tein, the latter also being present in plasma AOPP. In
our opinion, the evidence that MPC could be obtained
by exposing plasma to hydroxyl radical confirmed that
MPC could be generated by oxidants, even if this hy-
droxyl radical–generating system involved reducing sys-
tems such as ascorbic acid and transition metals. Indeed,
protein reduction would prevent disulfide bridges and
decreased protein cross-linking.
The report of the group of Dr. Lipinski extends the
concept of the biologic and pathophysiologic relevance of
oxidatively modified proteins. We have recently reported
that AOPP could induce interleukin (IL)-8 synthesis
by neutrophils and by monocytes, thus corroborating
our previous results that demonstrate that AOPP are in-
flammatory mediators [2]. Therefore, further investiga-
tion on the involvement of AOPP and/or MPC should be
performed, especially in diabetic or in uremic patients.
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